Virtual Library

Start Your Search

Murry Wynes



Author of

  • +

    OA01 - Precision Medicine and Personalized Therapy for Lung Cancer (ID 1)

    • Event: NACLC 2019
    • Type: Oral Abstract Session
    • Track:
    • Presentations: 1
    • +

      OA01.10 - Comparing Regional Results from the IASLC Global Survey on Molecular Testing in Lung Cancer (ID 37)

      14:00 - 15:40  |  Author(s): Murry Wynes

      • Abstract
      • Slides

      Background:
      The IASLC conducted an international survey to evaluate current practice and barriers to molecular testing (MT). We compared results from US/Canada to other regions of the world.


      Method:
      The survey contains a 7-question introduction, followed by 1 of 3 specific tracks: 32 questions for those requesting tests/treating patients, 45 questions on performing/interpreting assays, and 24 questions on tissue acquisition. Respondents also provided barriers to implementing/offering MT in free-response fields. Surveys were available in 7 languages and translated into English for analysis. IASLC criteria were used to group responses into the following geographic regions: US/Canada, Asia, Europe, Latin America, and the rest of the world (Other). P-values reported are for comparisons across regions using the Chi-squared test, free-text was analyzed with Nvivo.


      Results:
      There were 2,537 responses from 102 countries. 11% of responses were from US/Canada, 52% Asia, 19% Europe, 11% Latin America, and 7% Other. Respondents varied by track: 66% requesting/treating, 12% performing/interpreting assays, 13% tissue specimen acquisition, and 8% not involved with MT. MT rates are low across the board but vary significantly by region (p<0.0001). 51% of respondents in the US/Canada who test/treat patients and 61% globally report that most patients in their country do not receive MT. The most frequent barrier to MT in US/Canada was cost (same for all regions), second-most is turn-around time, which differs between regions. Other frequently reported barriers were quality/standards, access, and awareness. 52% of respondents who perform/interpret assays are unsure/not satisfied with the state of MT in their country, with 45% reporting this in the USA/Canada (p=0.0066). 29% of respondents who test/treat patients report that it took >10 days to receive results, occurring most frequently in USA/Canada (60%) (p<0.0001). Globally, 37% have trouble understanding MT result reports, most of whom cited a need for more technical and scientific knowledge (22% in USA/Canada, p<0.0001). 23% of respondents who perform/interpret assays reported >10% of cases are rejected due to inadequate samples (19% in USA/Canada, p=0.5590); However, 47% stated there is no policy or strategy to improve the quality of the tissue samples in their country. Finally, 33% of all respondents (26% USA/Canada, p=0.0041) were not aware of CAP/IASLC/AMP guidelines for MT.


      Conclusion:
      MT usage varies globally, and common barriers include cost, time, quality, and awareness. Many respondents were not satisfied with the state of MT in lung cancer and many were unaware of existing guidelines. Global and regional strategies should be developed to address these barriers.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.